Citigroup Lowers Bruker (NASDAQ:BRKR) Price Target to $75.00

Bruker (NASDAQ:BRKR) had its price target cut by equities research analysts at Citigroup from $80.00 to $75.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Citigroup’s price objective would indicate a potential upside of 23.99% from the company’s current price.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company reduced their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday. TD Cowen reduced their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday. Barclays dropped their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Finally, The Goldman Sachs Group dropped their price target on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a research note on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and an average target price of $79.36.

Bruker Trading Up 2.6 %

Shares of NASDAQ:BRKR opened at $60.49 on Wednesday. The company has a market cap of $9.16 billion, a PE ratio of 25.10, a P/E/G ratio of 2.32 and a beta of 1.20. The company’s 50 day moving average is $63.83 and its two-hundred day moving average is $66.47. Bruker has a 52 week low of $54.55 and a 52 week high of $94.86. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 11.29% and a return on equity of 24.92%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same quarter in the prior year, the business earned $0.74 earnings per share. The firm’s quarterly revenue was up 16.4% on a year-over-year basis. Equities analysts predict that Bruker will post 2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BRKR. Norden Group LLC lifted its holdings in shares of Bruker by 41.8% during the first quarter. Norden Group LLC now owns 5,944 shares of the medical research company’s stock worth $558,000 after purchasing an additional 1,753 shares during the period. Larson Financial Group LLC purchased a new stake in shares of Bruker in the first quarter valued at about $178,000. Texas Permanent School Fund Corp increased its stake in shares of Bruker by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 81,161 shares of the medical research company’s stock worth $7,624,000 after acquiring an additional 1,050 shares during the period. Duality Advisers LP raised its holdings in Bruker by 12.5% during the first quarter. Duality Advisers LP now owns 8,619 shares of the medical research company’s stock worth $810,000 after purchasing an additional 958 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its position in Bruker by 3.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 13,606 shares of the medical research company’s stock valued at $1,278,000 after purchasing an additional 432 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.